ArticleIntestinal research2020
Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study.
Article in Intestinal research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Inflammatory Bowel Disease in Kazakhstan: Phenotypes, Disease Activity, and Treatment Patterns from a National Registry.Journal of clinical medicine · 2026Article
- A systematic review of inflammatory bowel disease in Kazakhstan: prevalence, risk factors, and genetic insights.Future science OA · 2025Review
- Awareness of inflammatory bowel disease among the general population of Al-Baha region, Saudi Arabia.Journal of medicine and life · 2024Article
- Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990-2019: A Comprehensive Analysis Based on the Global Burden of Disease Study.Journal of epidemiology and global health · 2023Article
- Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea.Digestive diseases and sciences · 2023Article
- Obesity and novel management of inflammatory bowel disease.World journal of gastroenterology · 2023Review
- Bronchoesophageal fistula in a patient with Crohn's disease receiving anti-tumor necrosis factor therapy.Clinical endoscopy · 2023Article
- Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study.Intestinal research · 2023Article
- The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries.United European gastroenterology journal · 2022Review
- Clinical Features and Long-term Prognosis of Crohn's Disease in Korea: Results from the Prospective CONNECT Study.Gut and liver · 2022Article
- Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis.The Korean journal of internal medicine · 2022Article
- Natural history of inflammatory bowel disease: a comparison between the East and the West.Intestinal research · 2022Review
- What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?Gut and liver · 2022Review
- Inflammatory bowel disease in Korea: epidemiology and pathophysiology.The Korean journal of internal medicine · 2022Review
- Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.The Korean journal of internal medicine · 2022Review
- Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease.Intestinal research · 2022Article
- Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.Gut and liver · 2022Article
- Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?Intestinal research · 2022Review
- Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn's disease in clinical remission: a pilot study.Intestinal research · 2022Article
- Changes in the Long-term Prognosis of Crohn's Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study.Gut and liver · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND/
aimsThere has been a paucity of published data on the epidemiology of inflammatory bowel disease (IBD) in Central Asia and Kazakhstan. Therefore, we aimed to study IBD prevalence and patient awareness among adults in Kazakhstan.
methodsThe cross-sectional study was carried out among subjects of both sexes aged 18 years and older using IBD Alert Questionnaire (CalproQuest), single fecal calprotectin test, and endoscopy with biopsy to verify IBD from January to December 2017, across regions of Kazakhstan. All participants were included in the study after providing informed consent.
resultsOut of 115,556 subjects, there were 128 confirmed IBD cases, in which 36 Crohn's disease (CD) and 92 ulcerative colitis (UC) cases identified. The age and sex-adjusted IBD prevalence were 113.9 (95% confidence interval [CI], 69.0-158.9) per 100,000 population. The age- and sex-adjusted prevalence for UC were 84.4 (95% CI, 44.8-123.9) and for CD were 29.5 (95% CI, 8.2-50.9) per 100,000 population.
conclusionsThis is the first report on the prevalence of IBD with a verified diagnosis in the Central Asia and could be used to better plan and allocate healthcare resources for IBD management program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.